An Improved in vitro Method for Determination of Serum "Insulin-Like" Activity

1960 ◽  
Vol 105 (3) ◽  
pp. 595-598 ◽  
Author(s):  
S. L. Steelman ◽  
R. Oslapas ◽  
R. D. Busch
1993 ◽  
Vol 43 (5) ◽  
pp. 1156-1159 ◽  
Author(s):  
Robert May ◽  
Brian Logue ◽  
Byrad Edwards ◽  
Swati Patel

2009 ◽  
Vol 366 (1-2) ◽  
pp. 111-116 ◽  
Author(s):  
Simon Gaisford ◽  
Anthony E. Beezer ◽  
Alistair H. Bishop ◽  
Michael Walker ◽  
David Parsons

Metabolism ◽  
1967 ◽  
Vol 16 (1) ◽  
pp. 47-56 ◽  
Author(s):  
John A. Owen ◽  
Richard W. Lindsay ◽  
Joe H. Gaskin ◽  
Guy Hollifield

Author(s):  
D. I. Zybin ◽  
A. S. Seregin ◽  
A. D. Askretkov ◽  
N. V. Orlova ◽  
Yu. A. Seregin ◽  
...  

Objectives. Developing reliable and accurate analytical methods is necessary for comparative pharmaceutical analysis using physicochemical, biological (in vitro), preclinical, and clinical trials. The main objective of this study was to develop and validate an in vitro method for determining the specific activity of the recombinant monoclonal antibody eculizumab.Methods. The method of indirect enzyme immunoassay was used in the study.Results. A method for determining the specific activity of the humanized recombinant monoclonal antibody eculizumab was described and validated for the first time. A comparative evaluation of the specific activity of Soliris® (Alexion Pharmaceuticals Inc., USA), and its biosimilar PRK-001 (Pharmapark, Russia) was performed using the developed method.Conclusions. The similarity of PRK-001 and the original Soliris® in relation to their specific activity, that is, binding to the human complement system C5 protein, was proved. 


2022 ◽  
Vol 2022 ◽  
pp. 1-10
Author(s):  
Yalda Mirzaei ◽  
Kerstin Hagemeister ◽  
Martina Hüffel ◽  
Timo Schwandt ◽  
René H. Tolba ◽  
...  

Background. Tissue glues can minimize treatment invasiveness, mitigate the risk of infection, and reduce surgery time; ergo, they have been developed and used in surgical procedures as wound closure devices beside sutures, staples, and metallic grafts. Regardless of their structure or function, tissue glues should show an acceptable microbial barrier function before being used in humans. This study proposes a novel in vitro method using Escherichia coli Lux and bioluminescence imaging technique to assess the microbial barrier function of tissue glues. Different volumes and concentrations of E. coli Lux were applied to precured or cured polyurethane-based tissue glue placed on agar plates. Plates were cultured for 1 h, 24 h, 48 h, and 72 h with bioluminescence signal measurement subsequently. Herein, protocol established a volume of 5 μL of a 1 : 100 dilution of E. coli Lux containing around 2 × 10 7  CFU/mL as optimal for testing polyurethane-based tissue glue. Measurement of OD600nm, determination of CFU/mL, and correlation with the bioluminescence measurement in p/s unit resulted in a good correlation between CFU/mL and p/s and demonstrated good reproducibility of our method. In addition, this in vitro method could show that the tested polyurethane-based tissue glue can provide a reasonable barrier against the microbial penetration and act as a bacterial barrier for up to 48 h with no penetration and up to 72 h with a low level of penetration through the material. Overall, we have established a novel, sensitive, and reproducible in vitro method using the bioluminescence imaging technique for testing the microbial barrier function of new tissue glues.


Diabetes ◽  
1965 ◽  
Vol 14 (7) ◽  
pp. 432-435 ◽  
Author(s):  
J. Steinke ◽  
J. S. Soeldner

1998 ◽  
Vol 128 (3) ◽  
pp. 651-660 ◽  
Author(s):  
Anna K. E. Åkerberg ◽  
Helena G. M. Liljeberg ◽  
Yvonne E. Granfeldt ◽  
Anders W. Drews ◽  
Inger M. E. Björck

2008 ◽  
Vol 71 (6) ◽  
pp. 1117-1118 ◽  
Author(s):  
Benjamin Choquenet ◽  
Céline Couteau ◽  
Eva Paparis ◽  
Laurence J. M. Coiffard

1956 ◽  
Vol 72 (5) ◽  
pp. 720-720 ◽  
Author(s):  
Z. Zolli ◽  
M. J. Gallian ◽  
G. S. Shea ◽  
K. E. Price

Sign in / Sign up

Export Citation Format

Share Document